Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CYP1A2 CRISPR/Cas9 KO Plasmid (h): sc-401178
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP1A2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CYP1A2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CYP1A2 Antibody (3B8C1): sc-53614
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP1A2 CRISPR/Cas9 KO Plasmid (h) | sc-401178 | 20 µg | $397.00 |
Overview
CYP1A2 encodes a microsomal cytochrome P450 monooxygenase that catalyzes oxidative metabolism of diverse xenobiotics and endogenous substrates, contributing to hepatic drug clearance and chemical detoxification. Its transcription is regulated by xenobiotic-sensing pathways, including aryl hydrocarbon receptor (AHR) signaling, and its enzymatic activity intersects with redox homeostasis through NADPH–P450 reductase coupling. Genetic and environmental variation in CYP1A2 can alter metabolic capacity, influencing susceptibility to adverse drug responses and differential sensitivity to procarcinogens. CYP1A2 is therefore frequently studied in pharmacogenomics, toxicology, and models of liver-specific metabolic function.
CYP1A2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CYP1A2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CYP1A2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CYP1A2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CYP1A2 protein expression.
This CRISPR knockout system enables efficient generation of CYP1A2-deficient cell models for investigation of CYP1A2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CYP1A2 exon(s) critical for CYP1A2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CYP1A2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CYP1A2 CRISPR/Cas9 KO Plasmid (h) and CYP1A2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CYP1A2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CYP1A2 HDR Plasmid (h) and CYP1A2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CYP1A2 homology arms to support homology-directed repair at defined CYP1A2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.